Vedanta Biosciences Inc. founded by PureTech Health PLC with technology from the laboratory of scientific co-founder Kenya Honda, MD, PhD, will use this latest influx of cash to conduct several trials of its novel drugs based on live commensal microbes in infectious and autoimmune disease indications. Vedanta will also use some of the funds to scale up its technology platform.
Vedanta Raises $50 Million For Microbiome Candidate Trials
Vedanta Biosciences, which is developing a new class of therapies designed to modulate the human microbiome, has raised $50 million through new equity investments to advance several of its programs into the clinic.